Have you purchased yours? Purchase your All-Access Pass Now - Get Networking Course & 60 Day Recording Access
Senior Vice President
QED Therapeutics
Dr. Li has over 15 years of drug discovery and translational research experience at both strategic and operational levels. Currently as SVP of Translational Medicine at QED/BridgeBio, he is responsible for translational research and companion diagnostics. Before joining QED, he was Vice President, Head of Oncology Research at Ignyta, a precision oncology company acquired by Roche in 2018. Prior to Ignyta, Dr. Li held various leadership positions at Pfizer and Johnson & Johnson. During his career, he has made key contributions to multiple oncology therapeutics, including axitinib, crizotinib, dacomitinib, palbociclib, lorlatinib and entrectinib.